



RECEIVED

OCT 18 2001

TECH CENTER 1600/2900

SEQUENCE LISTING

<110> Kisiday, John  
Grodzinsky, Alan  
Zhang, Shuguang

<120> Peptide Scaffold Encapsulation of Tissue  
Cells and Uses Thereof

<130> 01997/537001

<140> US 09/778,200

<141> 2001-02-06

<160> 43

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 1

Arg Ala Asp Ala Arg Ala Asp Ala Arg Ala Asp Ala Arg Ala Asp Ala  
1 5 10 15

<210> 2

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 2

Arg Ala Asp Ala Arg Gly Asp Ala Arg Ala Asp Ala Arg Gly Asp Ala  
1 5 10 15

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 3

Arg Ala Asp Ala Arg Ala Asp Ala  
1 5

<210> 4  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 4  
Arg Ala Arg Ala Asp Ala Asp Ala Arg Ala Arg Ala Asp Ala Asp Ala  
1 5 10 15

<210> 5  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 5  
Arg Ala Arg Ala Asp Ala Asp Ala  
1 5

<210> 6  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 6  
Ala Glu Ala Lys Ala Glu Ala Lys Ala Glu Ala Lys Ala Glu Ala Lys  
1 5 10 15

<210> 7  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 7  
Ala Glu Ala Lys Ala Glu Ala Lys  
1 5

<210> 8  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 8

Arg Ala Glu Ala Arg Ala Glu Ala Arg Ala Glu Ala Arg Ala Glu Ala  
1 5 10 15

<210> 9

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 9

Arg Ala Glu Ala Arg Ala Glu Ala  
1 5

<210> 10

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 10

Lys Ala Asp Ala Lys Ala Asp Ala Lys Ala Asp Ala Lys Ala Asp Ala  
1 5 10 15

<210> 11

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 11

Lys Ala Asp Ala Lys Ala Asp Ala  
1 5

<210> 12

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 12

Ala Glu Ala Glu Ala His Ala His Ala Glu Ala Glu Ala His Ala His  
1 5 10 15

<210> 13

<211> 8

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 13  
Ala Glu Ala Glu Ala His Ala His  
1 5

<210> 14  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 14  
Phe Glu Phe Glu Phe Lys Phe Lys Phe Glu Phe Glu Phe Lys Phe Lys  
1 5 10 15

<210> 15  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 15  
Phe Glu Phe Lys Phe Glu Phe Lys  
1 5

<210> 16  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 16  
Leu Glu Leu Glu Leu Lys Leu Lys Leu Glu Leu Glu Leu Lys Leu Lys  
1 5 10 15

<210> 17  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 17

Leu Glu Leu Glu Leu Lys Leu Lys  
1 5

<210> 18  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 18  
Ala Glu Ala Glu Ala Lys Ala Lys Ala Glu Ala Glu Ala Lys Ala Lys  
1 5 10 15

<210> 19  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 19  
Ala Glu Ala Glu Ala Glu Ala Glu Ala Lys Ala Lys  
1 5 10

<210> 20  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 20  
Ala Glu Ala Glu Ala Lys Ala Lys  
1 5

<210> 21  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 21  
Lys Ala Lys Ala Lys Ala Lys Ala Glu Ala Glu Ala Glu Ala Glu Ala  
1 5 10 15

<210> 22  
<211> 16  
<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 22

Ala Glu Ala Glu Ala Glu Ala Glu Ala Lys Ala Lys Ala Lys Ala Lys  
1 5 10 15

<210> 23

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 23

Arg Ala Arg Ala Arg Ala Arg Ala Asp Ala Asp Ala Asp Ala Asp Ala  
1 5 10 15

<210> 24

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 24

Ala Asp Ala Asp Ala Asp Ala Asp Ala Arg Ala Arg Ala Arg Ala Arg  
1 5 10 15

<210> 25

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 25

Asp Ala Asp Ala Asp Ala Asp Ala Arg Ala Arg Ala Arg Ala Arg Ala  
1 5 10 15

<210> 26

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 26

Ala Asp Ala Asp Ala Asp Ala Asp Ala Arg Ala Arg Ala Arg Ala Arg

1

5

10

15

&lt;210&gt; 27

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed Peptide

&lt;400&gt; 27

His	Glu	His	Glu	His	Lys	His	Lys	His	Glu	His	Glu	His	Lys	His	Lys
1				5				10						15	

&lt;210&gt; 28

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed Peptide

&lt;400&gt; 28

His	Glu	His	Glu	His	Lys	His	Lys
1				5			

&lt;210&gt; 29

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed Peptide

&lt;400&gt; 29

Val	Glu	Val	Glu	Val	Glu	Val	Glu	Val	Glu	Val	Glu	Val	Glu	Val	Glu
1				5				10					15		
Val	Glu	Val	Glu												
				20											

&lt;210&gt; 30

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Designed Peptide

&lt;400&gt; 30

Arg	Phe	Arg	Phe	Arg	Phe	Arg	Phe	Arg	Phe	Arg	Phe	Arg	Phe	Arg	Phe
1				5				10					15		
Arg	Phe	Arg	Phe												
				20											

<210> 31  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 31  
Arg Gly Asp Tyr Arg Tyr Asp Tyr Arg Tyr Asp Tyr Arg Gly Asp Tyr  
1 5 10 15

<210> 32  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 32  
Arg Gly Asp Phe Arg Phe Asp Phe Arg Phe Asp Phe Arg Gly Asp Phe  
1 5 10 15

<210> 33  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 33  
Arg Gly Asp Trp Arg Trp Asp Trp Arg Trp Asp Trp Arg Gly Asp Trp  
1 5 10 15

<210> 34  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 34  
Arg Ala Asp Tyr Arg Tyr Glu Tyr Arg Tyr Glu Tyr Arg Ala Asp Tyr  
1 5 10 15

<210> 35  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide



<400> 35

Arg Ala Asp Phe Arg Phe Asp Phe Arg Phe Asp Phe Arg Ala Asp Phe  
1 5 10 15

<210> 36

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 36

Arg Ala Asp Trp Arg Trp Asp Trp Arg Trp Asp Trp Arg Ala Asp Trp  
1 5 10 15

<210> 37

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 37

Arg Gly Asp Tyr Arg Tyr Asp Tyr Thr Phe Arg Glu Glu Glu Gly Leu  
1 5 10 15  
Gly Ser Arg Tyr Asp Tyr Arg Gly Asp Tyr  
20 25

<210> 38

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 38

Arg Gly Asp Tyr Arg Tyr Asp Tyr Thr Phe Lys Glu Glu Glu Gly Leu  
1 5 10 15  
Gly Ser Arg Tyr Asp Tyr Arg Gly Asp Tyr  
20 25

<210> 39

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Designed Peptide

<400> 39

Arg Gly Asp Tyr Arg Tyr Asp Tyr Thr Ala Ser Glu Leu Glu Gly Arg  
1 5 10 15

Gly Thr Arg Tyr Asp Tyr Arg Gly Asp Tyr  
20 25

<210> 40  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 40  
Arg Gly Asp Tyr Arg Tyr Asp Tyr Ala Pro Thr Ala Gln Glu Ala Gly  
1 5 10 15  
Glu Gly Pro Arg Tyr Asp Tyr Arg Gly Asp Tyr  
20 25

<210> 41  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 41  
Arg Gly Asp Tyr Arg Tyr Asp Tyr Pro Thr Ile Ser Gln Glu Leu Gly  
1 5 10 15  
Gln Arg Pro Arg Tyr Asp Tyr Arg Gly Asp Tyr  
20 25

<210> 42  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 42  
Arg Gly Asp Tyr Arg Tyr Asp Tyr Pro Thr Val Ser Gln Glu Leu Gly  
1 5 10 15  
Gln Arg Pro Arg Tyr Asp Tyr Arg Gly Asp Tyr  
20 25

<210> 43  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Designed Peptide

<400> 43  
Lys Leu Asp Leu Lys Leu Asp Leu Lys Leu Asp Leu

Cont  
AS

1

5

10

0590  
1023

#5

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/778,200

DATE: 11/06/2001

TIME: 10:57:03

Input Set : A:\01997.537001.SEQLIST.TXT

Output Set: N:\CRF3\11062001\I778200.raw

4 <110> APPLICANT: Kisiday, John  
5 Grodzinsky, Alan  
6 Zhang, Shuguang  
8 <120> TITLE OF INVENTION: Peptide Scaffold Encapsulation of Tissue  
9 Cells and Uses Thereof  
12 <130> FILE REFERENCE: 01997/537001  
14 <140> CURRENT APPLICATION NUMBER: US 09/778,200  
C--> 15 <141> CURRENT FILING DATE: 2000-02-06  
17 <160> NUMBER OF SEQ ID NOS: 43  
19 <170> SOFTWARE: FastSEQ for Windows Version 4.0  
21 <210> SEQ ID NO: 1  
22 <211> LENGTH: 16  
23 <212> TYPE: PRT  
24 <213> ORGANISM: Artificial Sequence  
26 <220> FEATURE:  
27 <223> OTHER INFORMATION: Designed Peptide  
29 <400> SEQUENCE: 1  
30 Arg Ala Asp Ala Arg Ala Asp Ala Arg Ala Asp Ala Arg Ala Asp Ala  
31 1 5 10 15  
34 <210> SEQ ID NO: 2  
35 <211> LENGTH: 16  
36 <212> TYPE: PRT  
37 <213> ORGANISM: Artificial Sequence  
39 <220> FEATURE:  
40 <223> OTHER INFORMATION: Designed Peptide  
42 <400> SEQUENCE: 2  
43 Arg Ala Asp Ala Arg Gly Asp Ala Arg Ala Asp Ala Arg Gly Asp Ala  
44 1 5 10 15  
47 <210> SEQ ID NO: 3  
48 <211> LENGTH: 8  
49 <212> TYPE: PRT  
50 <213> ORGANISM: Artificial Sequence  
52 <220> FEATURE:  
53 <223> OTHER INFORMATION: Designed Peptide  
55 <400> SEQUENCE: 3  
56 Arg Ala Asp Ala Arg Ala Asp Ala  
57 1 5  
60 <210> SEQ ID NO: 4  
61 <211> LENGTH: 16  
62 <212> TYPE: PRT  
63 <213> ORGANISM: Artificial Sequence  
65 <220> FEATURE:  
66 <223> OTHER INFORMATION: Designed Peptide  
68 <400> SEQUENCE: 4  
69 Arg Ala Arg Ala Asp Ala Asp Ala Arg Ala Arg Ala Asp Ala Asp Ala  
70 1 5 10 15  
73 <210> SEQ ID NO: 5

ENTERED

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/778,200

DATE: 11/06/2001

TIME: 10:57:03

Input Set : A:\01997.537001.SEQLIST.TXT

Output Set: N:\CRF3\11062001\I778200.raw

```

74 <211> LENGTH: 8
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <223> OTHER INFORMATION: Designed Peptide ✓
81 <400> SEQUENCE: 5
82 Arg Ala Arg Ala Asp Ala Asp Ala
83 1 5
86 <210> SEQ ID NO: 6
87 <211> LENGTH: 16
88 <212> TYPE: PRT
89 <213> ORGANISM: Artificial Sequence
91 <220> FEATURE:
92 <223> OTHER INFORMATION: Designed Peptide ✓
94 <400> SEQUENCE: 6
95 Ala Glu Ala Lys Ala Glu Ala Lys Ala Glu Ala Lys
96 1 5 10 15
99 <210> SEQ ID NO: 7
100 <211> LENGTH: 8
101 <212> TYPE: PRT
102 <213> ORGANISM: Artificial Sequence
104 <220> FEATURE:
105 <223> OTHER INFORMATION: Designed Peptide ✓
107 <400> SEQUENCE: 7
108 Ala Glu Ala Lys Ala Glu Ala Lys
109 1 5
112 <210> SEQ ID NO: 8
113 <211> LENGTH: 16
114 <212> TYPE: PRT
115 <213> ORGANISM: Artificial Sequence
117 <220> FEATURE:
118 <223> OTHER INFORMATION: Designed Peptide ✓
120 <400> SEQUENCE: 8
121 Arg Ala Glu Ala Arg Ala Glu Ala Arg Ala Glu Ala Arg Ala Glu Ala
122 1 5 10 15
125 <210> SEQ ID NO: 9
126 <211> LENGTH: 8
127 <212> TYPE: PRT
128 <213> ORGANISM: Artificial Sequence
130 <220> FEATURE:
131 <223> OTHER INFORMATION: Designed Peptide ✓
133 <400> SEQUENCE: 9
134 Arg Ala Glu Ala Arg Ala Glu Ala
135 1 5
138 <210> SEQ ID NO: 10
139 <211> LENGTH: 16
140 <212> TYPE: PRT
141 <213> ORGANISM: Artificial Sequence
143 <220> FEATURE:

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/778,200

DATE: 11/06/2001

TIME: 10:57:03

Input Set : A:\01997.537001.SEQLIST.TXT

Output Set: N:\CRF3\11062001\I778200.raw

144 <223> OTHER INFORMATION: Designed Peptide  
 146 <400> SEQUENCE: 10  
 147 Lys Ala Asp Ala Lys Ala Asp Ala Lys Ala Asp Ala Lys Ala Asp Ala  
 148 1 5 10 15  
 151 <210> SEQ ID NO: 11  
 152 <211> LENGTH: 8  
 153 <212> TYPE: PRT  
 154 <213> ORGANISM: Artificial Sequence  
 156 <220> FEATURE:  
 157 <223> OTHER INFORMATION: Designed Peptide ✓  
 159 <400> SEQUENCE: 11  
 160 Lys Ala Asp Ala Lys Ala Asp Ala  
 161 1 5  
 164 <210> SEQ ID NO: 12  
 165 <211> LENGTH: 16  
 166 <212> TYPE: PRT  
 167 <213> ORGANISM: Artificial Sequence  
 169 <220> FEATURE:  
 170 <223> OTHER INFORMATION: Designed Peptide ✓  
 172 <400> SEQUENCE: 12  
 173 Ala Glu Ala Glu Ala His Ala His Ala Glu Ala Glu Ala His Ala His  
 174 1 5 10 15  
 177 <210> SEQ ID NO: 13  
 178 <211> LENGTH: 8  
 179 <212> TYPE: PRT  
 180 <213> ORGANISM: Artificial Sequence  
 182 <220> FEATURE:  
 183 <223> OTHER INFORMATION: Designed Peptide ✓  
 185 <400> SEQUENCE: 13  
 186 Ala Glu Ala Glu Ala His Ala His  
 187 1 5  
 190 <210> SEQ ID NO: 14  
 191 <211> LENGTH: 16  
 192 <212> TYPE: PRT  
 193 <213> ORGANISM: Artificial Sequence  
 195 <220> FEATURE:  
 196 <223> OTHER INFORMATION: Designed Peptide ✓  
 198 <400> SEQUENCE: 14  
 199 Phe Glu Phe Glu Phe Lys Phe Lys Phe Glu Phe Glu Phe Lys Phe Lys  
 200 1 5 10 15  
 203 <210> SEQ ID NO: 15  
 204 <211> LENGTH: 8  
 205 <212> TYPE: PRT  
 206 <213> ORGANISM: Artificial Sequence  
 208 <220> FEATURE:  
 209 <223> OTHER INFORMATION: Designed Peptide ✓  
 211 <400> SEQUENCE: 15  
 212 Phe Glu Phe Lys Phe Glu Phe Lys  
 213 1 5

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/778,200

DATE: 11/06/2001

TIME: 10:57:03

Input Set : A:\01997.537001.SEQLIST.TXT

Output Set: N:\CRF3\11062001\I778200.raw

216 <210> SEQ ID NO: 16  
217 <211> LENGTH: 16  
218 <212> TYPE: PRT  
219 <213> ORGANISM: Artificial Sequence  
221 <220> FEATURE:  
222 <223> OTHER INFORMATION: Designed Peptide ✓  
224 <400> SEQUENCE: 16  
225 Leu Glu Leu Glu Leu Lys Leu Lys Leu Glu Leu Glu Leu Lys Leu Lys  
226 1 5 10 15  
229 <210> SEQ ID NO: 17  
230 <211> LENGTH: 8  
231 <212> TYPE: PRT  
232 <213> ORGANISM: Artificial Sequence  
234 <220> FEATURE:  
235 <223> OTHER INFORMATION: Designed Peptide ✓  
237 <400> SEQUENCE: 17  
238 Leu Glu Leu Glu Leu Lys Leu Lys  
239 1 5  
242 <210> SEQ ID NO: 18  
243 <211> LENGTH: 16  
244 <212> TYPE: PRT  
245 <213> ORGANISM: Artificial Sequence  
247 <220> FEATURE:  
248 <223> OTHER INFORMATION: Designed Peptide ✓  
250 <400> SEQUENCE: 18  
251 Ala Glu Ala Glu Ala Lys Ala Lys Ala Glu Ala Glu Ala Lys Ala Lys  
252 1 5 10 15  
255 <210> SEQ ID NO: 19  
256 <211> LENGTH: 12  
257 <212> TYPE: PRT  
258 <213> ORGANISM: Artificial Sequence  
260 <220> FEATURE:  
261 <223> OTHER INFORMATION: Designed Peptide ✓  
263 <400> SEQUENCE: 19  
264 Ala Glu Ala Glu Ala Glu Ala Glu Ala Lys Ala Lys  
265 1 5 10  
268 <210> SEQ ID NO: 20  
269 <211> LENGTH: 8  
270 <212> TYPE: PRT  
271 <213> ORGANISM: Artificial Sequence  
273 <220> FEATURE:  
274 <223> OTHER INFORMATION: Designed Peptide ✓  
276 <400> SEQUENCE: 20  
277 Ala Glu Ala Glu Ala Lys Ala Lys  
278 1 5  
281 <210> SEQ ID NO: 21  
282 <211> LENGTH: 16  
283 <212> TYPE: PRT  
284 <213> ORGANISM: Artificial Sequence

## RAW SEQUENCE LISTING

DATE: 11/06/2001

PATENT APPLICATION: US/09/778,200

TIME: 10:57:03

Input Set : A:\01997.537001.SEQLIST.TXT

Output Set: N:\CRF3\11062001\I778200.raw

286 <220> FEATURE:  
287 <223> OTHER INFORMATION: Designed Peptide ✓  
289 <400> SEQUENCE: 21  
290 Lys Ala Lys Ala Lys Ala Lys Ala Glu Ala Glu Ala Glu Ala Glu Ala  
291 1 5 10 15  
294 <210> SEQ ID NO: 22  
295 <211> LENGTH: 16  
296 <212> TYPE: PRT  
297 <213> ORGANISM: Artificial Sequence  
299 <220> FEATURE:  
300 <223> OTHER INFORMATION: Designed Peptide ✓  
302 <400> SEQUENCE: 22  
303 Ala Glu Ala Glu Ala Glu Ala Glu Ala Lys Ala Lys Ala Lys Ala Lys  
304 1 5 10 15  
307 <210> SEQ ID NO: 23  
308 <211> LENGTH: 16  
309 <212> TYPE: PRT  
310 <213> ORGANISM: Artificial Sequence  
312 <220> FEATURE:  
313 <223> OTHER INFORMATION: Designed Peptide ✓  
315 <400> SEQUENCE: 23  
316 Arg Ala Arg Ala Arg Ala Arg Ala Asp Ala Asp Ala Asp Ala Asp Ala  
317 1 5 10 15  
320 <210> SEQ ID NO: 24  
321 <211> LENGTH: 16  
322 <212> TYPE: PRT  
323 <213> ORGANISM: Artificial Sequence  
325 <220> FEATURE:  
326 <223> OTHER INFORMATION: Designed Peptide ✓  
328 <400> SEQUENCE: 24  
329 Ala Asp Ala Asp Ala Asp Ala Arg Ala Arg Ala Arg Ala Arg  
330 1 5 10 15  
333 <210> SEQ ID NO: 25  
334 <211> LENGTH: 16  
335 <212> TYPE: PRT  
336 <213> ORGANISM: Artificial Sequence  
338 <220> FEATURE:  
339 <223> OTHER INFORMATION: Designed Peptide ✓  
341 <400> SEQUENCE: 25  
342 Asp Ala Asp Ala Asp Ala Asp Ala Arg Ala Arg Ala Arg Ala Arg Ala  
343 1 5 10 15  
346 <210> SEQ ID NO: 26  
347 <211> LENGTH: 16  
348 <212> TYPE: PRT  
349 <213> ORGANISM: Artificial Sequence ✓  
351 <220> FEATURE:  
352 <223> OTHER INFORMATION: Designed Peptide  
354 <400> SEQUENCE: 26  
355 Ala Asp Ala Asp Ala Asp Ala Asp Ala Arg Ala Arg Ala Arg Ala Arg



VERIFICATION SUMMARY

PATENT APPLICATION: US/09/778,200

DATE: 11/06/2001

TIME: 10:57:04

Input Set : A:\01997.537001.SEQLIST.TXT

Output Set: N:\CRF3\11062001\I778200.raw

L:15 M:271 C: Current Filing Date differs, Replaced Current Filing Date